Anticoagulation Management and Reversal

Reversal of antithrombotic agents. (odpre novo okno)

Bauer KA.

Vir‎: Am J Hematol 2012;87 Suppl 1:S119-26.

Indeksirano‎: PubMed 22460529

DOI‎: 10.1002/ajh.23165

https://www.ncbi.nlm.nih.gov/pubmed/22460529 (odpre novo okno)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (odpre novo okno)

Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M

Vir‎: J Thromb Haemost 2015;13(10):1790-8.

Indeksirano‎: PubMed 26270886

DOI‎: 10.1111/jth.13117

https://www.ncbi.nlm.nih.gov/pubmed/26270886 (odpre novo okno)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (odpre novo okno)

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators

Vir‎: N Engl J Med 2019;380(14):1326-35.

Indeksirano‎: PubMed 30730782

DOI‎: 10.1056/NEJMoa1814051

https://www.ncbi.nlm.nih.gov/pubmed/30730782 (odpre novo okno)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (odpre novo okno)

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators

Vir‎: N Engl J Med 2016;375(12):1131-41.

Indeksirano‎: PubMed 27573206

DOI‎: 10.1056/NEJMoa1607887

https://www.ncbi.nlm.nih.gov/pubmed/27573206 (odpre novo okno)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (odpre novo okno)

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M

Vir‎: Circulation 2011;124(14):1573-9.

Indeksirano‎: PubMed 21900088

DOI‎: 10.1161/CIRCULATIONAHA.111.029017

https://www.ncbi.nlm.nih.gov/pubmed/21900088 (odpre novo okno)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (odpre novo okno)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Vir‎: Lancet 2015;385(9982):2077-87.

Indeksirano‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (odpre novo okno)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (odpre novo okno)

Gordon JL, Fabian TC, Lee MD, Dugdale M

Vir‎: J Trauma Acute Care Surg 2013;75(3):475-86.

Indeksirano‎: PubMed 24089118

DOI‎: 10.1097/TA.0b013e3182a07391

https://www.ncbi.nlm.nih.gov/pubmed/24089118 (odpre novo okno)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (odpre novo okno)

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Vir‎: Am J Hematol 2012;87 Suppl 1:S141-5.

Indeksirano‎: PubMed 22473649

DOI‎: 10.1002/ajh.23202

https://www.ncbi.nlm.nih.gov/pubmed/22473649 (odpre novo okno)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (odpre novo okno)

Levi M, Eerenberg E, Kamphuisen PW.

Vir‎: J Thromb Haemost 2011;9(9):1705-12.

Indeksirano‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (odpre novo okno)

Emergency reversal of warfarin anticoagulation. (odpre novo okno)

Lin Y, Callum J.

Vir‎: CMAJ 2010;182(18):2004.

Indeksirano‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (odpre novo okno)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (odpre novo okno)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Vir‎: Thromb Haemost 2012;108(2):217-24.

Indeksirano‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (odpre novo okno)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (odpre novo okno)

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

Vir‎: J Thromb Haemost 2008;6(4):622-31.

Indeksirano‎: PubMed 18208533

DOI‎: 10.1111/j.1538-7836.2008.02904.x

https://www.ncbi.nlm.nih.gov/pubmed/18208533 (odpre novo okno)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (odpre novo okno)

Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Schünemann HJ, Nieuwlaat R

Vir‎: Blood Adv 2019;3(2):158-67.

Indeksirano‎: PubMed 30658963

DOI‎: 10.1182/bloodadvances.2018024133

https://www.ncbi.nlm.nih.gov/pubmed/30658963 (odpre novo okno)

Idarucizumab for dabigatran reversal. (odpre novo okno)

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI.

Vir‎: N Engl J Med 2015;373(6):511-20.

Indeksirano‎: PubMed 26095746

DOI‎: 10.1056/NEJMoa1502000

https://www.ncbi.nlm.nih.gov/pubmed/26095746 (odpre novo okno)

Idarucizumab for dabigatran reversal - full cohort analysis. (odpre novo okno)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Vir‎: N Engl J Med 2017;377(5):431-41.

Indeksirano‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (odpre novo okno)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (odpre novo okno)

Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B

Vir‎: Blood 2003;102(13):4594-9.

Indeksirano‎: PubMed 12920042

DOI‎: 10.1182/blood-2002-11-3566

https://www.ncbi.nlm.nih.gov/pubmed/12920042 (odpre novo okno)

Role of agents for reversing the effects of target-specific oral anticoagulants. (odpre novo okno)

Riley TR, Gauthier-Lewis ML, Sanchez CK, Douglas JS

Vir‎: Am J Health Syst Pharm 2017;74(2):54-61.

Indeksirano‎: PubMed 27895055

DOI‎: 10.2146/ajhp150810

https://www.ncbi.nlm.nih.gov/pubmed/27895055 (odpre novo okno)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (odpre novo okno)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Vir‎: Anesth Analg 2011;113(4):703-10.

Indeksirano‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (odpre novo okno)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (odpre novo okno)

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS

Vir‎: J Am Coll Cardiol 2017;70(24):3042-67.

Indeksirano‎: PubMed 29203195

DOI‎: 10.1016/j.jacc.2017.09.1085

https://www.ncbi.nlm.nih.gov/pubmed/29203195 (odpre novo okno)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (odpre novo okno)

Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, Pombra J, Akins PT, Axelrod YK, Ge IY, Sheridan WF, Flint AC.

Vir‎: World Neurosurg 2014;81(1):110-5.

Indeksirano‎: PubMed 23220122

DOI‎: 10.1016/j.wneu.2012.12.002

https://www.ncbi.nlm.nih.gov/pubmed/23220122 (odpre novo okno)

Reversal of warfarin-induced hemorrhage in the emergency department. (odpre novo okno)

Zareh M, Davis A, Henderson S.

Vir‎: West J Emerg Med 2011;12(4):386-92.

Indeksirano‎: PubMed 22224125

DOI‎: 10.5811/westjem.2011.3.2051

https://www.ncbi.nlm.nih.gov/pubmed/22224125 (odpre novo okno)

INTENZIVNA NEGA

Anticoagulation Management and Reversal

slovenščina

Anticoagulation Management and Reversal

https://assetsnffrgf-a.akamaihd.net/assets/ct/46e9307b0a/images/syn_placeholder_sqr.png

Anticoagulation Management and Reversal

Reversal of antithrombotic agents. (odpre novo okno)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (odpre novo okno)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (odpre novo okno)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (odpre novo okno)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (odpre novo okno)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (odpre novo okno)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (odpre novo okno)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (odpre novo okno)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (odpre novo okno)

Emergency reversal of warfarin anticoagulation. (odpre novo okno)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (odpre novo okno)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (odpre novo okno)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (odpre novo okno)

Idarucizumab for dabigatran reversal. (odpre novo okno)

Idarucizumab for dabigatran reversal - full cohort analysis. (odpre novo okno)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (odpre novo okno)

Role of agents for reversing the effects of target-specific oral anticoagulants. (odpre novo okno)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (odpre novo okno)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (odpre novo okno)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (odpre novo okno)

Reversal of warfarin-induced hemorrhage in the emergency department. (odpre novo okno)

Kontaktirajte z lokalnim predstavnikom

Paketi informacij za zdravnike

Videoposnetki

Anticoagulation Management and Reversal

Izberite svoj jezik

Deli povezavo